Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
In this single-center, randomized, open-label, crossover, prospective clinical trial, a total
of 120 AML patients who achieved remission will be randomized into two groups, of 60 cases in
each group. Each subject is required to undergo two cycles of chemotherapy. At the treatment
cycle, patients received subcutaneous injection of rhTPO. At the control cycle, rhTPO therapy
is not given.The safety of rhTPO is evaluated by the monitoring of liver and renal functions,
blood coagulation, and TPO-neutralizing antibody, and adverse events associated with rhTPO
treatment are recorded during the study period.